System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Christoffer Gebhardt is an expert in Oncology at University Medical Center Hamburg-Eppendorf (Germany). As of October 2026, ScienceLeadR ranks Christoffer Gebhardt in the top 1% of experts worldwide for Skin Neoplasms and Melanoma. Christoffer Gebhardt has authored 258 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 8 of them ongoing. SLR score: 1,258 (community average: 125). How the SLR is computed.

LeadR Profile

Christoffer Gebhardt University Medical Center Hamburg-Eppendorf Germany
1 258 ScienceLeadR Reputation 1258

Unlock

Register Login
Network Map

Oncology

Subspecialties: Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1993 - 2026
Source: PubMed

University Medical Center Hamburg-Eppendorf

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 258

Citations

Citations: 10 602 1st author: 40 Last author: 59 Unique author: 6

Main journals

Eur J Cancer 20
J Dtsch Dermatol Ges 19
Int J Cancer 14
J Eur Acad Dermatol Venereol 13
Cancers (Basel) 11

Best Journals

Ann Oncol 5
Cancer Cell 1
J Clin Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC-TRIM registry.
PMID 42855830 — registries, cells, merkel cells, therapeutics, carcinoma, merkel cell		Br J Dermatol20260
Beyond the Surface of Long-term Survival in Stage IV Melanoma: A Multicenter Cross-sectional Study.
PMID 42760605 — radiotherapy, financial stress, cross-sectional studies, melanoma, neoplasms, survivorship, therapeutics, dermatology		Br J Dermatol20260
Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma.
PMID 42760578 — research design, biomedical research, melanoma, neoplasms, biomarkers, tumor burden, neoplasm metastasis, therapeutics		J Transl Med20260
Incidence and Predictors of Immune-Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real-World Cohort Study.
PMID 42723137 — incidence, melanoma, thyroiditis, neoplasms, cohort studies, thyroid gland, drug therapy, immunotherapy, hypothyroidism, therapeutics, chemotherapy		Int J Cancer20260
Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study.
PMID 42564088 — melanoma, multiple chronic conditions, immune system diseases, therapeutics		Front Immunol20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 8
Phase 2 6
N/A 2
Phase 1 2
Phase 2/Phase 3 1
Phase 4 1

By status:

Recruiting 7
Completed 6
Terminated 4
Active not recruiting 2
Unknown 1

By type:

Interventional 18
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 1
multicentricup10 17

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical study of V940 and pembrolizumab in people with melanoma (V940 012)
2024-519605-36-00 — melanoma, rna, messenger		Phase 2Recruiting2025
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 — melanoma, rna, messenger		Phase 3Active not recruiting2023
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127)
2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab		Phase 3Recruiting2023
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD 1 Inhibitor Cemiplimab
NCT07387198 — skin, cells, merkel cells, lymph nodes, neoplasms, sentinel lymph node, solutions, immunotherapy, lymph, therapeutics, genes, mcc, carcinoma, merkel cell, skin neoplasms, carcinoma		Phase 2Recruiting2026
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First Line Therapy in Patients With Advanced Melanoma
NCT06697301 — toll-like receptors, safety, melanoma, neoplasms, neoplasm metastasis, therapeutics, toll-like receptor 7		Phase 2/Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS